Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study

BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784). HYPOTHESIS: Because previous real‐world studies have not reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Camm, A. John, Amarenco, Pierre, Haas, Sylvia, Bach, Miriam, Kirchhof, Paulus, Kuhls, Silvia, Lambelet, Marc, Turpie, Alexander G.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724214/
https://www.ncbi.nlm.nih.gov/pubmed/32896928
http://dx.doi.org/10.1002/clc.23452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724214/
https://www.ncbi.nlm.nih.gov/pubmed/32896928
http://dx.doi.org/10.1002/clc.23452

Ejemplares similares